Lazertinib + SBRT：EGFR 突变寡转移 NSCLC 的 2026 放疗组合信号
类型: 临床研究 / SBRT + 三代EGFR TKI 发表日期: 2026-01-27 入库日期: 2026-05-21 来源: PubMed / ESMO Open 标签: EGFR L858R, 放疗, SBRT, Lazertinib, 寡转移, 三代TKI, 局部治疗
Citation
Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer. ESMO Open. 2026. PMID: 41604814. DOI: 10.1016/j.esmoop.2025.106057
Related trial design: ABLATE, KCSG-LU21-11. Clinical Lung Cancer. 2022. PMID: 36002368. DOI: 10.1016/j.cllc.2022.07.014
Why it matters for mom
This is not a direct treatment instruction. Mom is on osimertinib-based therapy, not lazertinib, and her disease course is later than first-line oligometastatic treatment. The value is conceptual and practical: modern EGFR care increasingly studies third-generation TKIs together with stereotactic radiation rather than treating radiation as only end-stage palliation.
Practical takeaways
- SBRT/local ablative RT is a legitimate discussion topic in EGFR-mutant disease when lesions are limited and targetable.
- Choice of EGFR TKI matters less for the family question than the principle: can local control safely extend the useful life of systemic therapy?
- Toxicity depends strongly on site: lung, sternum/chest wall, spine, and mediastinum have different risks.
- This should be weighed against marrow reserve, chemotherapy plans, and biopsy needs.
Questions for doctors
- Is any current lesion suitable for SBRT rather than conventional palliative radiation?
- What dose/fraction schedule would be considered for sternum/parasternal disease, and what are chest wall/skin/pain risks?
- Would local radiation allow continuing current systemic therapy longer, or is systemic progression too broad?